Investors
Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.
press release
March 27, 2019
press release
March 13, 2019
Geneva, Switzerland and Boston – March 13, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of…
Read morepress release
March 5, 2019
Major 2018 Accomplishments Driven by Positive Clinical Trial Results –Significant increase in rates of pregnancy and live birth (up to…
Read moreJune 29, 2023
May 18, 2022
ObsEva Announces Update on Board of Directors
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 18, 2024 –…
Read moreMedia
Chemin des Aulx,12
1228, Plan-Les-Ouates, Geneva, Switzerland
+41 (0)22 552 3840